GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
FiercePharma4d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
MM&M4d
GSK highlights positive Blenrep data from Phase 3 trial at ASH
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
pharmaphorum4d
ASH: Blenrep ups survival by 42% in multiple myeloma trial
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
GSK Gets Positive Results in Blood-Cancer Drug Trial
Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...
MedCity News5d
GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH
Clinical trial investigators and the company believe these results could support making the GSK drug, Blenrep, a new standard of care treatment for this type of blood cancer. The new trial results ...
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...
GSK announces NMPA of China accepted review of NDA for Blenrep
GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...
STAT4d
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...